MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 462250 | Name: BJE6-106
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

BJE6-106 is a potent, selective 3rd generation PKCδ inhibitor. It possesses tumor-specific effect.

Chemical Structure

BJE6-106
BJE6-106
CAS#1564249-38-2

Theoretical Analysis

MedKoo Cat#: 462250

Name: BJE6-106

CAS#: 1564249-38-2

Chemical Formula: C26H23NO2

Exact Mass: 381.1729

Molecular Weight: 381.48

Elemental Analysis: C, 81.86; H, 6.08; N, 3.67; O, 8.39

Price and Availability

Size Price Availability Quantity
5mg USD 350.00 2 Weeks
10mg USD 650.00 2 Weeks
25mg USD 1,250.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
BJE6-106; BJE6 106; BJE6106; B106
IUPAC/Chemical Name
6-(2-(9H-carbazol-9-yl)ethyl)-2,2-dimethyl-2H-chromene-8-carbaldehyde
InChi Key
QLDDENZBVHBRKN-UHFFFAOYSA-N
InChi Code
InChI=1S/C26H23NO2/c1-26(2)13-11-19-15-18(16-20(17-28)25(19)29-26)12-14-27-23-9-5-3-7-21(23)22-8-4-6-10-24(22)27/h3-11,13,15-17H,12,14H2,1-2H3
SMILES Code
O=CC1=C2C(C=CC(C)(C)O2)=CC(CCN3C4=C(C5=C3C=CC=C5)C=CC=C4)=C1
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Product Data
Instruction
View handling instruction
Biological target:
BJE6-106 (B106) is a 3rd generation PKCδ inhibitor with an IC50 of 0.05 μM and targets selectivity over classical PKC isozyme PKCα (IC50=50 μM).
In vitro activity:
Therefore, this study tested the effect of a recently described specific PKCδ inhibitor, B106, on growth and survival of UM cell lines. Surprisingly, this study found that B106 efficiently induced apoptosis in several cell lines, but apparently independent of activated PKCδ. Reference: ACS Chem Biol. 2019 Jan 18;14(1):132-136. https://pubmed.ncbi.nlm.nih.gov/30525429/
In vivo activity:
TBD
Solvent mg/mL mM comments
Solubility
DMSO 50.0 131.07
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 381.48 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Heijkants R, Teunisse A, de Vries J, Ovaa H, Jochemsen A. Selective PKCδ Inhibitor B106 Elicits Uveal Melanoma Growth Inhibitory Effects Independent of Activated PKC Isoforms. ACS Chem Biol. 2019 Jan 18;14(1):132-136. doi: 10.1021/acschembio.8b00292. Epub 2019 Jan 2. PMID: 30525429.
In vitro protocol:
1. Heijkants R, Teunisse A, de Vries J, Ovaa H, Jochemsen A. Selective PKCδ Inhibitor B106 Elicits Uveal Melanoma Growth Inhibitory Effects Independent of Activated PKC Isoforms. ACS Chem Biol. 2019 Jan 18;14(1):132-136. doi: 10.1021/acschembio.8b00292. Epub 2019 Jan 2. PMID: 30525429.
In vivo protocol:
TBD
1: Takashima A, English B, Chen Z, et al. Protein kinase Cδ is a therapeutic target in malignant melanoma with NRAS mutation. ACS Chem Biol. 2014;9(4):1003-1014. doi:10.1021/cb400837t